18 completed, 2 recruiting, 1 unknown. 9 Phase 2, 7 Phase 1, 4 Phase 3, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Completed 9 |
| Phase 1 | 7 | Completed 5, Recruiting 2 |
| Phase 3 | 4 | Completed 4 |
| Phase 4 | 1 | Completed 1 |
Follow tezacaftor: new trials by email Literature Review of tezacaftor trials Research Report on tezacaftor
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-272 in Healthy Participants VX-272, Placebo, Tezacaftor - Cystic Fibrosis | Phase 1 | Recruiting | Vertex Pharmaceuticals Incorporated | 160 | 2026-02-25 | 2026-09-23 |
| Evaluation of VX-581 in Healthy Participants and in Participants With Cystic Fibrosis VX-581, Placebo, D-IVA - Cystic Fibrosis | Phase 1 | Recruiting | Vertex Pharmaceuticals Incorporated | 152 | 2025-12-09 | 2026-10-19 |
| Evaluation of VX-828 in Healthy Participants and in Participants With Cystic Fibrosis VX-828, Placebo, Itraconazole - Cystic Fibrosis | Phase 1 | Completed | Vertex Pharmaceuticals Incorporated | 165 | 2023-12-12 | 2026-08-10 |
| Trikafta for Patients With Non-cystic Fibrosis Bronchiectasis Trikafta - Non-cystic Fibrosis Bronchiectasis | Phase 4 | Completed | Emory University | 32 | 2023-04-18 | 2026-02-09 |
| Daily Monitoring of Respiratory Symptoms and Spirometry During ETI Treatment in Persons With Cystic Fibrosis. Elexacaftor 100 MG / Ivacaftor 75 MG / Tezacaftor 50 MG, 2 tablets each morning + Ivacaftor 150 mg one tablet each evening - Cystic Fibrosis | Unknown | CHC Montlegia | 20 | 2022-09-01 | 2022-10-31 | |
| Trikafta in Cystic Fibrosis Patients Trikafta - Cystic Fibrosis | Phase 2 | Completed | Emory University | 42 | 2019-09-04 | 2026-08-11 |
| Gut Imaging for Function & Transit in Cystic Fibrosis Study 2 Tezacaftor/Ivacaftor + Ivacaftor, Placebo oral tablet - Cystic Fibrosis | Phase 2 | Completed | Nottingham University Hospitals NHS Trust | 12 | 2019-09-03 | 2023-05-24 |
| A Study to Evaluate the Safety and Efficacy of VX-121 Combination Therapy in Subjects With Cystic Fibrosis VX-121, TEZ, VX-561 - Cystic Fibrosis | Phase 2 | Completed | Vertex Pharmaceuticals Incorporated | 87 | 2019-04-30 | 2023-04-20 |
| A Study to Evaluate Efficacy and Safety of TEZ/IVA in Subjects Aged 6 Through 11 Years With Cystic Fibrosis TEZ/IVA, IVA, Placebo - Cystic Fibrosis | Phase 3 | Completed | Vertex Pharmaceuticals Incorporated | 67 | 2018-05-17 | 2020-02-11 |
| A Study Evaluating the Safety and Efficacy of VX-659 Combination Therapy in Subjects With Cystic Fibrosis VX-659, TEZ/IVA, IVA - Cystic Fibrosis | Phase 2 | Completed | Vertex Pharmaceuticals Incorporated | 124 | 2017-08-08 | 2021-04-22 |
| A Study of VX-445 in Healthy Subjects and Subjects With Cystic Fibrosis IVA, TEZ/IVA, VX-445 - Cystic Fibrosis | Phase 1 / Phase 2 | Completed | Vertex Pharmaceuticals Incorporated | 225 | 2017-01-23 | 2022-01-18 |
| A Study to Evaluate Safety and Pharmacokinetics of VX-659 in Healthy Subjects and in Adults With Cystic Fibrosis VX-659, Tezacaftor, Ivacaftor - Cystic Fibrosis | Phase 1 | Completed | Vertex Pharmaceuticals Incorporated | 163 | 2016-11-01 | 2017-09-05 |
| A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of VX-661/Ivacaftor in Pediatric Subjects With Cystic Fibrosis (CF) TEZ, TEZ/IVA, IVA - Cystic Fibrosis | Phase 3 | Completed | Vertex Pharmaceuticals Incorporated | 83 | 2016-11-01 | 2020-03-04 |
| A Study Evaluating the Safety and Efficacy of VX-440 Combination Therapy in Subjects With Cystic Fibrosis TEZ, IVA, VX-440 - Cystic Fibrosis | Phase 2 | Completed | Vertex Pharmaceuticals Incorporated | 74 | 2016-10-01 | 2020-08-28 |
| A Study Evaluating Safety and Pharmacokinetics of VX-440 in Combination With Tezacaftor/Ivacaftor in Healthy Adult Subjects VX-440, TEZ, IVA - Cystic Fibrosis | Phase 1 | Completed | Vertex Pharmaceuticals Incorporated | 16 | 2016-07-20 | 2018-04-03 |
| A Phase 2 Study to Evaluate Effects of VX-661/Ivacaftor on Lung and Extrapulmonary Systems in Subjects With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation Tezacaftor/Ivacaftor, Ivacaftor, Tezacaftor/Ivacaftor matching placebo - Cystic Fibrosis | Phase 2 | Completed | Vertex Pharmaceuticals Incorporated | 34 | 2016-02-01 | 2021-07-19 |
| A Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Heterozygous for the F508del-CFTR Mutation VX-661 plus ivacaftor combination, Ivacaftor, Placebo (matched to VX-661 plus ivacaftor combination) - Cystic Fibrosis | Phase 3 | Completed | Vertex Pharmaceuticals Incorporated | 168 | 2015-08-01 | 2018-06-12 |
| A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor VX-661 Plus Ivacaftor Combination, Ivacaftor, VX-661 Plus Ivacaftor Combination Placebo - Cystic Fibrosis | Phase 3 | Completed | Vertex Pharmaceuticals Incorporated | 510 | 2015-01-01 | 2018-06-12 |
| Study to Evaluate Safety and Efficacy of VX-661 in Combination With Ivacaftor in Subjects With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation With an Open-Label Expansion VX-661, Ivacaftor, Placebo matched to VX-661 - Cystic Fibrosis | Phase 2 | Completed | Vertex Pharmaceuticals Incorporated | 40 | 2014-03-01 | 2025-09-24 |
| An Open-Label, Phase 1 Study in Healthy Adult Subjects to Examine the Effects of Multiple-Dose Ciprofloxacin on Ivacaftor and VX-661 in Combination With Ivacaftor ivacaftor, VX-661, ciprofloxacin - Cystic Fibrosis | Phase 1 | Completed | Vertex Pharmaceuticals Incorporated | 34 | 2014-01-01 | 2014-03-26 |
Showing 20 of 21. Sign in to see all of them.
Cystic Fibrosis (20) · Signs and Symptoms, Respiratory (1)
Vertex Pharmaceuticals Incorporated (17) · Emory University (2) · CHC Montlegia (1) · Nottingham University Hospitals NHS Trust (1)
United States (15) · United Kingdom (9) · Canada (5) · Germany (5) · Australia (4) · Belgium (4) · Denmark (3) · France (3) · Ireland (3) · Netherlands (3) · Spain (3) · Austria (2) · Israel (2) · Italy (2) · Switzerland (2)
Eric Sorscher, MD (2) · Alan Smyth, Prof (1) · Giles Major, Dr (1) · Patrick Lebecque, PhD (1) · Scott Donaldson, MD (1)
PMID 33331662, PMID 37983082, PMID 30334693, PMID 29099344, PMID 30334692, PMID 31253540, PMID 32546431, PMID 36509366, PMID 36842446, PMID 39139270, PMID 39208836, PMID 39951444, PMID 42271629
2016 (5), 2017 (2), 2014 (1), R01HL139876 (1)